Tilray Inc. ($TLRY) Stock Forecast: Down 5.2% Today

What is Tilray Inc.?

Tilray (TLRY) is a cannabis company known for its innovative products and expanding market presence. The stock has been experiencing significant volatility in the market recently.

Why is Tilray Inc. going down?

TLRY stock is down 5.2% on Jan 6, 2026 16:42

• The bearish movement in Tilray's stock today can be attributed to multiple factors:
• The formation of a bearish head-and-shoulders pattern, indicating a potential trend reversal and investor caution.
• Heightened volatility ahead of the earnings release, with analysts expecting significant price swings and a projected loss per share.
• The company's expansion into non-alcoholic, cannabis-infused beverages for its "Dry January" campaign might not have been well-received by investors, impacting the stock negatively.
• Investors are closely monitoring Tilray's financial results release on January 9th, potential cannabis reclassification efforts in the US, and the impact of increased competition in the US market for further insights into the stock's performance.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Tilray Brands Expands Dry January Offerings with Zero-Proof Spirits, Non-Alcoholic Beers and Hemp-Derived THC Beverages

Tilray Brands is expanding its Dry January offerings with a new collection of zero-proof spirits, non-alcoholic beers, and hemp-derived THC beverages. This move caters to the growing "sober curious" movement and consumer demand for sophisticated, mindful drinking options. The collection includes THC cocktails and seltzers, non-alcoholic spirits replicating popular alcohol types, and various non-alcoholic craft beers.

https://finance.yahoo.com/news/tilray-brands-expands-dry-january-120000314.html

Tilray stock forms a risky pattern: Jan. 8 will be key

Tilray stock has shown extreme volatility, surging then dropping significantly, and is now forming a bearish head-and-shoulders pattern. Key factors influencing its price include potential cannabis reclassification efforts in the US and the upcoming financial results release on January 9th, with analysts expecting flat revenue growth. Investors are also watching for the impact of increased competition if Tilray expands into the US market.

https://www.tradingview.com/news/invezz:05bd91f3d094b:0-tilray-stock-forms-a-risky-pattern-jan-8-will-be-key/

Tilray Shares Face Heightened Volatility Ahead of Earnings Release

Tilray Brands, Inc. is preparing to release quarterly financial results, causing heightened volatility in its stock. The company's shares are trading lower ahead of the announcement, with analysts expecting significant price swings and a projected loss per share. Tilray is also launching a "Dry January" marketing campaign for its non-alcoholic, cannabis-infused beverages to diversify its revenue.

https://www.ad-hoc-news.de/boerse/news/ueberblick/tilray-shares-face-heightened-volatility-ahead-of-earnings-release/68463715

Tilray Brands (NASDAQ:TLRY) Trading Down 2.3% - Here's Why

Tilray Brands (NASDAQ:TLRY) stock experienced a 2.3% decline during midday trading on Monday, with 5.83 million shares traded. The stock traded below its 50- and 200-day moving averages at approximately $10.45, closing at $9.72 previously. Analyst ratings are mixed, with a consensus "Hold" rating and a target price of $20.00, despite some upgrades from "Strong Sell" to "Hold" by Wall Street Zen and Atb Cap Markets, and a reaffirmation of "Sell" by Weiss Ratings.

https://www.marketbeat.com/instant-alerts/tilray-brands-nasdaqtlry-trading-down-23-heres-why-2026-01-05/

Top Stocks With Earnings This Week: Tilray, Applied Digital and More

This article outlines key earnings reports scheduled for the first full week of 2026, featuring companies in the cannabis, AI infrastructure, and consumer goods sectors. Investors will be monitoring reports from companies such as Albertsons, Cal-Maine Foods, Applied Digital, Constellation Brands, Commercial Metals, Neogen, Helen of Troy, The Simply Good Foods Co., Tilray Brands, and Aehr Test Systems for insights into market navigation and future strategies. Special attention will be on Applied Digital's HPC data centers and Tilray's expansion strategy following recent federal rescheduling news in the U.S.

https://www.benzinga.com/markets/earnings/26/01/49712584/top-stocks-with-earnings-this-week-tilray-applied-digital-and-more

Trending Today

First Solar Inc. ($FSLR) Stock Forecast: Down 8.5% Today

Marvell Technology Group Ltd. ($MRVL) Stock Forecast: Down 9.0% Today

Amgen Inc. ($AMGN) Stock Forecast: Up 5.0% Today

Intel Corporation ($INTC) Stock Forecast: Up 7.1% Today

Alibaba Group Holding Limited ($BABA) Stock Forecast: Down 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Down 6.0% Today

Cardano ($ADA) Crypto Forecast: Down 5.6% Today

Bittensor ($TAO) Crypto Forecast: Down 5.4% Today

Vaulta (prev.EOS) ($A) Crypto Forecast: Down 5.1% Today

ZCash ($ZEC) Crypto Forecast: Down 6.8% Today

Tilray Inc. Price History

22.11.2025 - TLRY Stock was down 5.2%

• The bearish movement in Tilray's stock today could be attributed to the company's ongoing financial struggles, lack of earnings, and cash burn.
• Despite recent positive sentiment and stock rises driven by potential easing of marijuana restrictions and strategic developments, the market may be reacting to the underlying financial challenges faced by Tilray.
• The uncertainty surrounding U.S. marijuana reform, particularly the reliance on federal rescheduling rather than outright legalization, might be causing investors to exercise caution and reevaluate their positions in Tilray.

22.11.2025 - TLRY Stock was down 6.0%

• The bearish movement in TLRY stock today could be attributed to the anticipation and uncertainty surrounding the upcoming financial results announcement.
• Comments on Tilray's lack of earnings may have contributed to investor skepticism and selling pressure on the stock.
• Despite the positive news about Tilray's formation of Tilray Medical USA, Inc. to advance its U.S. medical cannabis operations, the overall market sentiment may have been overshadowed by concerns about the company's financial performance and growth strategy.
• The market might be reacting to the realization that Tilray's growth is primarily driven by acquisitions in the alcohol sector rather than its struggling cannabis segment, raising doubts about the company's long-term sustainability.

19.11.2025 - TLRY Stock was down 8.4%

• There was a significant bearish movement in TLRY stock today, possibly due to investors cashing out profits following a recent surge triggered by indications of potential marijuana reclassification by a former President.
• Market reaction may be influenced by experts warning that moving cannabis to Schedule III doesn't mean federal legalization, causing uncertainty and prompting selling.
• Despite forming Tilray Medical USA, Inc. to expand U.S. medical cannabis operations, the company's financial difficulties, ongoing losses, and focus on alcohol acquisitions rather than cannabis growth could be fueling negative market sentiment.
• The uncertain regulatory landscape for cannabis, paired with a recent reverse split and general market instability, may be intensifying downward pressure on Tilray's stock price.

16.11.2025 - TLRY Stock was up 5.8%

• TLRY experienced a substantial surge of 44.1% following potential discussions of a reclassification of marijuana at a federal level. This positive news not only impacted TLRY but also other cannabis stocks like Canopy Growth and Aurora Cannabis.
• The company's recent execution of a 10-for-1 reverse stock split, aimed at reducing its float and ensuring compliance with Nasdaq regulations, also influenced the bullish movement by boosting investor confidence.
• Surpassing its 200-day moving average and holding a Zacks Rank #3 (Hold) indicate a potential long-term bullish trend for TLRY, supported by positive earnings estimate revisions and strategic expansion into new markets.
• While the future looks promising, caution is advised due to the volatility in the cannabis sector. It is advisable for investors to closely monitor the situation until official confirmation and details regarding the potential policy change are disclosed.

24.11.2025 - TLRY Stock was down 5.3%

• The upcoming announcement of Tilray Brands' second fiscal quarter financial results has likely created uncertainty and caution among investors, leading to a sell-off of the stock.
• Despite the recent drop, the stock has shown a notable increase over the past month, indicating potential profit-taking by traders.
• The lack of substantial analysis suggests a disconnect between market sentiment and speculative opinions on whether the stock's fall presents a buying opportunity.
• Investors are eagerly awaiting the earnings report, with expectations of a significant increase in EPS, but a slight decrease in revenue compared to the previous year, adding to the volatility surrounding the stock.

06.00.2026 - TLRY Stock was down 5.2%

• The bearish movement in Tilray's stock today can be attributed to multiple factors:
• The formation of a bearish head-and-shoulders pattern, indicating a potential trend reversal and investor caution.
• Heightened volatility ahead of the earnings release, with analysts expecting significant price swings and a projected loss per share.
• The company's expansion into non-alcoholic, cannabis-infused beverages for its "Dry January" campaign might not have been well-received by investors, impacting the stock negatively.
• Investors are closely monitoring Tilray's financial results release on January 9th, potential cannabis reclassification efforts in the US, and the impact of increased competition in the US market for further insights into the stock's performance.

17.11.2025 - TLRY Stock was down 8.1%

• Despite positive developments regarding the potential reclassification of marijuana from Schedule I to Schedule III, Tilray faced a bearish movement.
• The surge in Tilray's stock price post speculations on marijuana reclassification by Trump might have prompted profit-taking actions among investors, leading to the bearish movement.
• Uncertainty surrounding the final reclassification decision and profit-taking activities likely contributed to Tilray's stock price decline today.
• The market sentiment towards Tilray remains optimistic, anticipating future ease in federal restrictions and potential improvements in profitability.

17.11.2025 - TLRY Stock was up 16.2%

• TLRY stock surged by 44.1% due to speculation about a possible reclassification of marijuana as a Schedule III substance through an executive order.
• The surge in TLRY's stock price was driven by optimism about relaxed federal restrictions on cannabis and the potential business opportunities it could bring for companies in the industry.
• Despite the initial rally, the stock price cooled off as White House officials indicated that no final decision had been reached, showcasing the uncertainty surrounding the potential reclassification of marijuana. This led to profit-taking and a moderation in TLRY's price movement.
• Tilray's CEO emphasized the importance of clear regulation in the cannabis industry, especially regarding THC-infused drinks. He highlighted how regulatory clarity could benefit legitimate companies by ensuring quality standards and reducing illicit market activity.

02.00.2026 - TLRY Stock was up 5.6%

• Tilray's stock is struggling to maintain momentum despite recent U.S. regulatory shifts and political support, trading below key technical levels.
• Investor focus is on the upcoming Q2 earnings report, with expectations of a loss per share on revenue. Analysts are looking for signs of financial progress from cost-saving measures and brand integrations.
• The stock's increased attention on social media platforms is sparking discussions about whether TLRY's current mid-single digit trading price reflects a genuine recovery or speculative hype.
• Analysts have a cautiously optimistic stance, considering potential U.S. policy changes and growth in Tilray's alcohol business, balanced against risks like weak cannabis sales and ongoing losses.

29.11.2025 - TLRY Stock was down 5.0%

• Tilray's stock price decreased by 4.2%, closing at $10.085, which was below the broader market performance.
• Analysts have given a consensus "Hold" rating with an average price target of $20, showing caution among investors.
• The drop in stock price may be linked to lower-than-expected performance and uncertainties about the upcoming second fiscal quarter results.
• Despite optimistic prospects for potential cannabis rescheduling and hemp-derived products, investors might be hesitant due to recent underperformance and competition in the AI sector.

29.11.2025 - TLRY Stock was down 5.0%

• Tilray's stock experienced a 4.2% decline in value during mid-day trading, closing at $10.085.
• Analysts have assigned a consensus "Hold" rating to Tilray, with a median price target of $20, indicating a potential upside of 88.49%.
• The bearish movement could be attributed to the cautious sentiment among analysts, despite potential positive developments such as cannabis rescheduling and revised product definitions.
• The upcoming announcement of Tilray's second fiscal quarter results may also be contributing to investor uncertainty and selling pressure on the stock.

19.11.2025 - TLRY Stock was down 23.1%

• Today's bearish movement in TLRY may be due to investors taking profits following a recent surge influenced by discussions of President Trump contemplating cannabis reclassification.
• Though there is optimism about regulatory changes, the speculative nature of the cannabis industry and uncertainties regarding federal legalization may be causing some traders to proceed with caution.
• Volatility in TLRY's stock price could be impacted by option traders anticipating significant year-end movements, leading to short-term market fluctuations.
• It is important for investors to stay informed about any official announcements on cannabis regulations to navigate the current market volatility effectively.